Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: Results of a phase II study from the German Hodgkin study group

Leukemia

Volumn 30, Issue 6, 2016, Pages 1425-1427

  Eichenauer, D A ^a   Goergen, H ^a   Plutschow A ^a   Wongso, D ^a   Behringer, K ^a   Kreissl, S ^a   Thielen, I ^a   Halbsguth, T ^a   Brockelmann P J ^a   Fuchs, M ^a   Boll B ^a   Von Tresckow, B ^a   Borchmann, P ^a   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LETTER; MALE; MULTIMODALITY CANCER THERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; CLINICAL TRIAL; GERMANY; HODGKIN DISEASE; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 84949604347     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.321     Document Type: Letter

References (14)

1. Eichenauer DA, Engert A. VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematol Oncol 2013; 31: 47-50.
2. Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118: 4363-4365.
3. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y et al. Mature results of a phase II study of rituximab therapy for nodular lymphocytepredominant Hodgkin lymphoma. J Clin Oncol 2014; 32: 912-918.
4. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109-111.
5. Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii70-iii75.
6. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM et al. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw 2015; 13: 554-586.
7. Eichenauer DA, Plutschow A, Fuchs M, von Tresckow B, Boll B, Behringer K et al. Long-term course of patients with stage IA nodular lymphocyte-predominant hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol 2015; 33: 2857-2862.
8. King MT, Donaldson SS, Link MP, Natkunam Y, Advani RH, Hoppe RT. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. Int J Radiat Oncol Biol Phys 2015; 92: 67-75.
9. Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434-439.
10. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant 2013; 19: 991-994.
11. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793-799.
12. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631-639.
13. Shet T, Panjwani P, Epari S, Sengar M, Prasad M, Arora B et al. A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 2014; 20: 1-8.
14. Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122: 4246-4252, quiz 4292.